Gene therapy trial aims to halt vision loss in rare eye disease
NCT ID NCT06699108
First seen Jan 10, 2026 · Last updated Apr 21, 2026 · Updated 11 times
Summary
This study is testing an experimental gene therapy called VGR-R01 for people with Bietti Crystalline Dystrophy, a rare genetic disease that causes progressive vision loss. The trial will enroll 45 adults to see if a one-time injection into the eye can slow or stop the decline in eyesight compared to a control group. The main goal is to measure changes in visual clarity and assess the treatment's safety.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INHERITED RETINAL DISEASES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shanghai Vitalgen Biopharma Co.,Ltd.
Shanghai, Shanghai Municipality, China
Conditions
Explore the condition pages connected to this study.